Therefore, the study indicated that the synergistic treatment of AR antagonists and 5α-reductase inhibitors could be a more promising glioblastoma therapeutic strategy.284 Zalcman et al. demonstrated that afatinib, an EGFR kinase inhibitor, can block AR activation and nuclear translocation in glioblastoma cells. The gene discussed is AR; the disease is glioblastoma.